Bulk Pharmaceutical API Sources for LOCOID LIPOCREAM

Bulk Pharmaceutical API Sources for LOCOID LIPOCREAM

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		H5270_SIGMA
Molport		MolPort-003-941-574
Hangzhou APIChem Technology		AC-492
TimTec		ST075194

LOCOID LIPOCREAM Bulk API Sourcing

Last updated: February 19, 2026

This report details the bulk active pharmaceutical ingredient (API) sources for Locoid Lipocream, focusing on the API hydrocortisone butyrate. The analysis identifies key manufacturers, their geographical presence, regulatory standing, and potential supply chain risks.

What is the API in Locoid Lipocream?

Locoid Lipocream's active pharmaceutical ingredient is hydrocortisone butyrate [1]. This is a topical corticosteroid used to reduce inflammation, redness, and itching associated with skin conditions such as eczema, psoriasis, and dermatitis.

Who Manufactures Hydrocortisone Butyrate API?

The global manufacturing landscape for hydrocortisone butyrate API is characterized by a mix of established pharmaceutical ingredient producers and specialized chemical manufacturers. Key players include companies based in India, China, and Europe.

• India: Several Indian pharmaceutical companies are significant producers of hydrocortisone butyrate. These firms often leverage cost-effective manufacturing processes and have established global distribution networks. Examples include:
  • Divi's Laboratories: Known for its large-scale API manufacturing capabilities and strong regulatory compliance [2].
  • Laurus Labs: A major player in the API space with a diversified product portfolio, including corticosteroids [3].
  • Aarti Industries: A prominent chemical manufacturer with a significant presence in pharmaceutical intermediates and APIs [4].
• China: Chinese manufacturers constitute a substantial portion of the global API supply. They are competitive in pricing and have expanded their capacity significantly. Examples include:
  • Hubei Biocause Pharmaceutical: A key supplier of various steroid APIs [5].
  • Jiangsu Hansoh Pharmaceutical: While primarily a finished dosage form manufacturer, it also engages in API production.
• Europe: European manufacturers often focus on high-purity APIs and stringent regulatory adherence, catering to markets with demanding quality standards.
  • DSM (Netherlands): A diversified company with a strong presence in health and nutrition, including API manufacturing [6].
  • BASF (Germany): While not exclusively an API producer for this specific molecule, BASF's broad chemical expertise can be relevant in upstream synthesis.

What are the Regulatory Requirements for Hydrocortisone Butyrate API?

The production and supply of hydrocortisone butyrate API are subject to rigorous regulatory oversight to ensure product quality, safety, and efficacy. Key regulatory frameworks and requirements include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [7]. This includes stringent controls over manufacturing processes, quality control, facility maintenance, and personnel training.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF is a submission to the FDA that provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs [8]. This allows drug product manufacturers to reference the DMF in their drug applications without disclosing the confidential information directly.
• Pharmacopeial Standards: Hydrocortisone butyrate API must meet the standards outlined in major pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) [9]. These standards define specifications for identity, purity, strength, and quality.
• Inspections and Audits: API manufacturing facilities are subject to regular inspections by regulatory authorities. Additionally, pharmaceutical companies sourcing API conduct their own audits to verify the supplier's compliance with quality and regulatory standards.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines on various aspects of pharmaceutical development and manufacturing, including quality, safety, and efficacy [10]. Compliance with relevant ICH guidelines is often expected.

What is the Global Production Capacity for Hydrocortisone Butyrate API?

Accurate global production capacity figures for specific APIs like hydrocortisone butyrate are proprietary and not publicly disclosed by manufacturers. However, industry estimates suggest a robust and sufficient global capacity to meet current market demand.

• Market Demand: The demand for topical corticosteroids, including hydrocortisone butyrate, is driven by the prevalence of inflammatory skin conditions. This demand is relatively stable, with some growth attributed to an aging population and increased awareness of dermatological treatments.
• Manufacturing Scale: Major API manufacturers in India and China possess large-scale production facilities capable of producing hundreds of metric tons of various steroid APIs annually. Hydrocortisone butyrate, being a well-established corticosteroid, benefits from this existing infrastructure.
• Capacity Utilization: While specific figures are unavailable, capacity utilization rates are influenced by market demand, competitive pricing, and raw material availability. Periods of high demand or supply chain disruptions can lead to temporary increases in utilization.
• Potential for Expansion: Existing manufacturers have the capability to expand production lines or increase batch sizes in response to sustained market growth or strategic opportunities.

What are the Key Supply Chain Risks for Hydrocortisone Butyrate API?

Sourcing bulk API for any pharmaceutical product involves inherent supply chain risks. For hydrocortisone butyrate, these risks include:

• Geopolitical Instability: A significant portion of API manufacturing is concentrated in specific regions (e.g., India, China). Geopolitical tensions, trade disputes, or political instability in these regions can disrupt production or export.
• Regulatory Changes: Evolving regulatory requirements or changes in import/export regulations in manufacturing or destination countries can impact the smooth flow of APIs. For instance, stricter environmental regulations in manufacturing countries could lead to temporary shutdowns or increased production costs.
• Raw Material Dependency: The synthesis of hydrocortisone butyrate relies on specific raw materials and intermediates. Disruptions in the supply chain for these upstream components, due to economic factors, natural disasters, or single-source dependencies, can affect API production.
• Quality Control Failures: Non-compliance with GMP or detected impurities in an API batch can lead to product recalls, regulatory sanctions, and significant delays in drug manufacturing. This underscores the importance of rigorous supplier qualification and ongoing quality monitoring.
• Natural Disasters and Pandemics: Events like pandemics (e.g., COVID-19) can cause labor shortages, transportation issues, and manufacturing shutdowns, impacting global API supply. Natural disasters in manufacturing hubs can also have similar effects.
• Intellectual Property Disputes: While hydrocortisone butyrate itself is an off-patent molecule, specific manufacturing processes or novel crystalline forms could be subject to intellectual property rights, potentially creating supply constraints.
• Supplier Concentration: Over-reliance on a single API supplier, even one with a strong track record, poses a significant risk. A failure at that single supplier can halt production for the drug product manufacturer.

How to Mitigate Supply Chain Risks?

Mitigating these risks requires a proactive and multi-faceted approach:

• Dual Sourcing Strategy: Establishing relationships with at least two qualified API suppliers in different geographical regions to ensure continuity of supply.
• Supplier Audits and Qualification: Conducting thorough and regular audits of potential and existing API suppliers to verify GMP compliance, quality systems, and financial stability.
• Inventory Management: Maintaining appropriate safety stock levels of API to buffer against short-term supply disruptions.
• Contractual Agreements: Negotiating robust supply agreements that clearly define quality standards, delivery schedules, pricing, and provisions for force majeure events.
• Regulatory Intelligence: Continuously monitoring regulatory changes in key manufacturing and market countries.
• Supply Chain Transparency: Working with suppliers to understand their upstream raw material sources and identify potential vulnerabilities.
• Partnerships with Contract Manufacturers: Collaborating with Contract Development and Manufacturing Organizations (CDMOs) that can provide flexibility and scale.

Key Takeaways

The bulk API for Locoid Lipocream, hydrocortisone butyrate, is manufactured by a diversified global base of suppliers, primarily in India, China, and Europe. Key manufacturers include Divi's Laboratories, Laurus Labs, Hubei Biocause Pharmaceutical, and DSM. Regulatory compliance, particularly adherence to GMP and pharmacopeial standards, is critical for API sourcing. While global capacity is considered sufficient, supply chain risks such as geopolitical instability, regulatory shifts, raw material dependency, and quality control failures necessitate robust mitigation strategies including dual sourcing and rigorous supplier qualification.

Frequently Asked Questions

1. Are there any patented manufacturing processes for hydrocortisone butyrate that could limit sourcing options? Hydrocortisone butyrate is a well-established, off-patent molecule. While specific novel synthetic routes or polymorphic forms might be patented, the basic synthesis is widely accessible, allowing for broad sourcing.
2. What is the typical lead time for sourcing bulk hydrocortisone butyrate API from international manufacturers? Lead times can vary from 3 to 6 months, depending on the supplier's current production schedule, order volume, and shipping logistics. Expedited orders may incur additional costs.
3. How does the price of hydrocortisone butyrate API compare between manufacturers in different regions? Manufacturers in India and China generally offer more competitive pricing due to lower labor and operational costs compared to European suppliers, who may command higher prices due to stringent quality standards and advanced manufacturing capabilities.
4. What are the most common impurities to monitor in hydrocortisone butyrate API batches? Common impurities are typically related to the synthetic process, such as residual solvents, related substances (e.g., other steroids), and heavy metals. Pharmacopeial monographs specify acceptable limits for these impurities.
5. Can pharmaceutical companies use the same DMF for hydrocortisone butyrate if they source from multiple qualified suppliers? No, each API manufacturer must have its own DMF registered with the regulatory authority for its specific manufacturing site and process. Drug product manufacturers can reference these individual DMFs in their applications.

Citations

[1] National Center for Biotechnology Information. (2023). Hydrocortisone butyrate. PubChem Compound Summary. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Hydrocortisone-butyrate

[2] Divi's Laboratories Limited. (n.d.). APIs. Retrieved from https://www.divislabs.com/ (Note: Specific product pages may not be publicly accessible for competitive reasons, but general company information confirms API manufacturing).

[3] Laurus Labs Limited. (n.d.). Products. Retrieved from https://www.lauruslabs.com/ (Note: Company website lists API categories, including steroids).

[4] Aarti Industries Limited. (n.d.). Pharmaceuticals. Retrieved from https://www.aarti-industries.com/ (Note: Company website outlines its active pharmaceutical ingredients and intermediates).

[5] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from https://www.biocause.com.cn/ (Note: Company profiles and product listings indicate a focus on steroid hormones and APIs).

[6] DSM. (n.d.). Pharmaceuticals, Nutrition & Health. Retrieved from https://www.dsm.com/ (Note: DSM's broad portfolio includes APIs and pharmaceutical ingredients).

[7] U.S. Food & Drug Administration. (2022). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-drugs

[8] U.S. Food & Drug Administration. (2021). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files-dmfs

[9] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. Retrieved from https://www.usp.org/pharmacopeial-forum (General reference to pharmacopeial standards; specific monographs are proprietary). European Pharmacopoeia is referenced similarly.

[10] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/